Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.
Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong SAR, China.
J Cancer Res Clin Oncol. 2021 May;147(5):1431-1442. doi: 10.1007/s00432-021-03588-5. Epub 2021 Mar 24.
The recent advancement in massively parallel sequencing technologies has empowered liquid biopsies, in particular circulating tumor DNA (ctDNA) analysis, to be the new paradigm in personalized cancer management. Plasma ctDNA detection overcomes the current limitations in tumor tissue procurement and serves as a convenient and non-invasive method to capture tumor heterogeneity and genetic evolution along patients' cancer journey. In breast cancer, the current clinical application of ctDNA includes real-time monitoring of tumor response, detection of drug-resistant clones, assessing dynamic variations in tumor mutational landscape, identifying actionable mutations, detecting minimal residual disease and screening of early tumor.
This review aims to summarize the current clinical evidence of ctDNA application in the management of breast cancer.
近年来，大规模平行测序技术的进步使液体活检，特别是循环肿瘤 DNA（ctDNA）分析，成为个性化癌症管理的新模式。血浆 ctDNA 检测克服了目前肿瘤组织获取的局限性，是一种方便、非侵入性的方法，可以捕获肿瘤异质性和遗传进化。在乳腺癌中，ctDNA 的当前临床应用包括实时监测肿瘤反应、检测耐药克隆、评估肿瘤突变景观的动态变化、鉴定可操作的突变、检测微小残留疾病和筛查早期肿瘤。
本综述旨在总结 ctDNA 在乳腺癌管理中的应用的临床证据。
